Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

In multiple myeloma patients, autologous stem cell transplants abrogate the difference of treating them with two or three drug combinations: Real world data from a single institution in a middle-income country.

View Full Paper
Ask AI
Bookmark
Share

Authors

OLOlivia D. LaraUniversity of North Carolina at Chapel HillMCMichelle Lavoignet CisnerosClínica RuizMCMiguel Gómez Cabrera

Discussion

Loading...

Member takes

Implication

Retrospective analysis shows autologous stem cell transplant enhances overall survival in multiple myeloma, implying possible treatment cost reductions.

Key Points

  • Evaluate the effectiveness of autologous stem cell transplants in multiple myeloma patients treated with two- or three-drug regimens.
  • Conducted a retrospective cohort study at a single institution from 1991 to 2025.
  • Grouped patients into dual therapy and triple therapy based on their treatment regimens.
  • Utilized Kaplan-Meier survival analysis and Cox proportional hazards models to compare outcomes.
  • Significant overall survival difference between two-drug (median OS: 230.7 months) and three-drug (median OS: 58.8 months) groups.
  • No significant difference in progression-free survival between groups.
  • Autologous stem cell transplant improved overall survival in both treatment cohorts.

Cite This Study

Lara et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d622https://doi.org/10.1182/blood-2025-7604
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost2024 · 1 citations
  2. 2Autologous HSCT with novel agent‐based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma2024 · 1 citations
  3. 3Comparison of tandem and single autologous stem cell transplantation in multiple myeloma: a retrospective propensity score-matching study2024
  4. 4Elderly (> 70 years) Multiple Myeloma Patients Benefit Equally from Autologous Hematopoietic Stem Cell Transplantation When Compared to Younger Patients2024
  5. 5Second autologous hematopoietic stem cell transplantation in multiple myeloma2026